LSD1 Promotes Prostate Cancer Cell Reprogramming by Repressing TP53 Signaling Independently of Its Demethylase Function

Scientists determined that lysine-specific demethylase 1 (LSD1) was highly upregulated in neuroendocrine prostate cancer (NEPC) vs. adenocarcinoma patient tumors. LSD1 suppression with RNAi or allosteric LSD1 inhibitors—but not catalytic inhibitors—reduced NEPC cell survival.